drugset / Trial / NCT07495852

Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

NCT07495852

Phase 3 Recruiting 510 enrolled Glaukos Corporation
RandomizedParallel-groupTriple-blindTreatment

Summary

Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

Timeline

Start
2026-02-17
Primary completion
2028-06
Completion
2032-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Timolol Other / unclassified 0.5 % Other
Subject Travoprost Other / unclassified Other

Indications